Signifikansi : harus dimonitoring secara ketaty

Golongan ACE inhibitor (Captopril, enalapril, lisinopril) + insulin lispro meningkatkan efek insulin lispro oleh sinergisme farmakodinamik digoxin + metformin digoksin akan meningkatkan kadar atau efek metformin by basic (cationic) drug competition for renal tubular clearance. B- Blocker (Bisoprolol, Carvedilol, Metoprolol) + Angiotensin Receptor Blocker (Candesartan, Valsartan) Efek sinergis secara farmakodinamik. Risiko mengalami kelainan janin jika diberikan pada ibu hamil. carvedilol + digoxin carvedilol meningkatkan kadar digoksin dengan cara meningkatkan absorpsi digoxin di GI, berlaku untuk penggunaan secara oral. Selain itu kadar digoksin ditingkatkan oleh carvedilol dengan cara menurunkan clearance digoksin di ginjal. ACE Inhibitor (Captopril, Enalapril, Lisinopril) + glyburide Captopril, enalapril dan lisinopril meningkatkan efek gliburid dengan sinergisme farmakodinamik. ACE Inhibitor (Captopril, Enalapril, Lisinopril) + digoxin Captopril, enalapril dan lisinopril meningkatkan kadar digoksin melalui mekanisme yang tidak diketahui B- Blocker (Bisoprolol, Carvedilol, Metoprolol) + digoxin bisoprolol meningkatkan efek digoksin secara sinergisme farmakodinamik. Enhanced bradycardia. furosemide + digoxin furosemid meningkatkan efek digoksin melalui sinergisme farmakodinamik. Digoksin menigkatkan efek hipokalemia. ACE Inhibitor (Captopril, Enalapril, Lisinopril) + furosemide Mekanisme sinergis secara farmakodinamik. Resiko hipotensi akut, insufisiensi ginjal ACE Inhibitor (Captopril, Enalapril, Lisinopril) + insulin glargine Captopril, enalapril, lisinopril meningkatkan efek digoksin melalui sinergisme farmakodinamik. candesartan + valsartan candesartan and valsartan both increase serum potassium. Significant - Monitor Closely.

y

y

y

y

y

y

y

y

y

y

y

candesartan + bisoprolol candesartan and bisoprolol both increase serum potassium. Significant - Monitor Closely.

y

candesartan + carvedilol candesartan and carvedilol both increase serum potassium. Significant - Monitor Closely.

y

candesartan + metoprolol candesartan and metoprolol both increase serum potassium. Significant - Monitor Closely.

y

candesartan + digoxin candesartan and digoxin both increase serum potassium. Significant - Monitor Closely.

y

candesartan + furosemide candesartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Significant - Monitor Closely.

y

valsartan + bisoprolol valsartan and bisoprolol both increase serum potassium. Significant - Monitor Closely.

y

valsartan + carvedilol valsartan and carvedilol both increase serum potassium. Significant - Monitor Closely.

y

valsartan + metoprolol valsartan and metoprolol both increase serum potassium. Significant - Monitor Closely.

y

valsartan + digoxin valsartan and digoxin both increase serum potassium. Significant - Monitor Closely.

y

valsartan + furosemide valsartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Significant - Monitor Closely.

y

bisoprolol + carvedilol bisoprolol and carvedilol both increase serum potassium. Significant - Monitor Closely.

y

bisoprolol + metoprolol bisoprolol and metoprolol both increase serum potassium. Significant - Monitor Closely.

y

bisoprolol + digoxin bisoprolol and digoxin both increase serum potassium. Significant - Monitor Closely.

y

bisoprolol + furosemide bisoprolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Significant - Monitor Closely.

y

carvedilol + metoprolol carvedilol and metoprolol both increase serum potassium. Significant - Monitor Closely.

y

carvedilol + digoxin carvedilol and digoxin both increase serum potassium. Significant - Monitor Closely.

y

carvedilol + furosemide carvedilol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Significant - Monitor Closely.

y

metoprolol + digoxin metoprolol and digoxin both increase serum potassium. Significant - Monitor Closely.

y

metoprolol + furosemide metoprolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Significant - Monitor Closely.

y

digoxin + furosemide digoxin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Significant - Monitor Closely.

y

hydralazine + bisoprolol hydralazine increases effects of bisoprolol by pharmacodynamic synergism. Significant Monitor Closely. Additive hypotensive effects.

y

hydralazine + carvedilol

hydralazine increases effects of carvedilol by pharmacodynamic synergism. Significant Monitor Closely. Additive hypotensive effects.y

hydralazine + metoprolol hydralazine increases effects of metoprolol by pharmacodynamic synergism. Significant Monitor Closely. Additive hypotensive effects.

y

carvedilol + hydralazine carvedilol increases effects of hydralazine by pharmacodynamic synergism. Significant Monitor Closely. Additive hypotensive effects.

y

digoxin + valsartan digoxin will increase the level or effect of valsartan by Other (see comment). Significant - Monitor Closely. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure

y

glyburide + valsartan glyburide will increase the level or effect of valsartan by Other (see comment). Significant - Monitor Closely. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure

y

repaglinide + valsartan repaglinide will increase the level or effect of valsartan by Other (see comment). Significant - Monitor Closely. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure

Minory

metformin + furosemide metformin decreases levels of furosemide by unspecified interaction mechanism. Minor or non-significant interaction.

y

furosemide + metformin furosemide increases levels of metformin by unspecified interaction mechanism. Minor or non-significant interaction.